Fenfluramine (Fintepla®) for Dravet Syndrome. HTA ID: 23048

Assessment Status NCPE assessment ongoing
HTA ID 23048
Drug Fenfluramine (Fintepla®)
Brand Fintepla®
Indication Fenfluramine (Fintepla®) is indicated for seizures associated with Dravet Syndrome (as an add-on therapy for patients two years of age and older).
Assessment Process
Rapid review commissioned 31/07/2023
Rapid review completed 07/09/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fenfluramine compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 29/09/2023
Pre-submission consultation with Applicant 07/11/2023
Full submission received from Applicant 16/05/2024
Preliminary review sent to Applicant 20/05/2024
NCPE assessment re-commenced 17/06/2024